Omnicell, Inc. (NASDAQ:OMCL) Receives Consensus Rating of “Hold” from Brokerages

Omnicell, Inc. (NASDAQ:OMCL) has received a consensus recommendation of “Hold” from the six brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $42.20.

Several analysts have weighed in on OMCL shares. Wells Fargo & Company decreased their price objective on shares of Omnicell from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Friday, February 9th. Barclays started coverage on shares of Omnicell in a research note on Wednesday, January 3rd. They set an “underweight” rating and a $33.00 price objective on the stock. Finally, Benchmark decreased their price target on shares of Omnicell from $42.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, February 9th.

Institutional Trading of Omnicell

Hedge funds have recently modified their holdings of the stock. Covestor Ltd grew its stake in shares of Omnicell by 65.6% during the third quarter. Covestor Ltd now owns 1,355 shares of the company’s stock valued at $61,000 after purchasing an additional 537 shares during the last quarter. Acadian Asset Management LLC bought a new position in Omnicell in the third quarter valued at approximately $62,000. Neo Ivy Capital Management bought a new position in Omnicell in the third quarter valued at approximately $78,000. Benjamin Edwards Inc. boosted its stake in Omnicell by 36.4% in the first quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock valued at $95,000 after acquiring an additional 868 shares during the last quarter. Finally, Fifth Third Bancorp boosted its stake in Omnicell by 143.2% in the third quarter. Fifth Third Bancorp now owns 2,230 shares of the company’s stock valued at $100,000 after acquiring an additional 1,313 shares during the last quarter. 97.70% of the stock is owned by institutional investors.

Omnicell Stock Down 1.7 %

Shares of Omnicell stock opened at $27.40 on Tuesday. The company has a quick ratio of 2.22, a current ratio of 2.52 and a debt-to-equity ratio of 0.48. Omnicell has a 1-year low of $25.69 and a 1-year high of $77.14. The firm’s 50-day moving average price is $27.64 and its two-hundred day moving average price is $32.04.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.22. The firm had revenue of $258.85 million for the quarter, compared to analysts’ expectations of $256.00 million. Omnicell had a negative net margin of 1.78% and a positive return on equity of 3.43%. On average, sell-side analysts expect that Omnicell will post 0.09 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.